PIONEER 6 — trial digest
PIONEER 6 (N Engl J Med 2019): Is oral semaglutide cardiovascular-safe?
Citation and design
| Field | Value |
|---|---|
| Trial | PIONEER 6 |
| Intervention | Oral semaglutide 14 mg daily |
| Publication | N Engl J Med, 2019 (first author Husain) |
| Design | Event-driven cardiovascular safety trial, median 15.9 months |
| Population | Adults with type 2 diabetes at high cardiovascular risk |
This digest summarises the trial and the criticisms our journal club considered material. It is not a substitute for the paper, and where the two differ the paper is right.
The question it set out to answer
Is oral semaglutide cardiovascular-safe?
Stating the question before the result is a house convention. A great many arguments about this trial are actually arguments about what it was for.
What it found
A pre-approval safety trial, designed and powered for non-inferiority rather than superiority.
Non-inferiority was met. Point estimates were favourable but the trial was not designed to establish benefit.
A good teaching example of why "the point estimate favoured the drug" is not the same as "the trial showed benefit".
Criticisms the journal club considered material
- Short duration and modest event numbers limit what can be concluded beyond safety.
- It is frequently cited as though it were an efficacy trial, which it is not.
These are criticisms of the design and of how the result is used, not of the investigators. Sessions that lose that distinction get moderated.
How it is misused
The two recurring misuses of this trial in general discussion are quoting the relative effect without the absolute one, and extending the result to a population the trial did not enrol. Both are easy to correct and both keep happening.
Where a number appears in secondary coverage without an estimand attached, assume it is whichever version is larger and check the paper.
Maintenance
Digests are reviewed when new analyses of the same trial are published, and at the review date shown above regardless. If a secondary publication changes the picture, raise it in journal club rather than editing the digest directly, so the change is discussed before it lands.
Revision history
| 2026-05-08 | dietitian_hollis | Citation sweep: two references did not support the sentences attached to them and have been replaced. |
| 2026-01-30 | q.zhao_qa | Recorded a dissent from one maintainer rather than resolving it silently. |
| 2025-09-12 | mira.patel | Reverted an unsourced change and asked the editor to re-apply it with a citation. |
| 2025-08-02 | PharmNotes_Whitfield | Annual review: checked every figure against its source. Two rounded values tightened. |
| 2025-05-11 | g.pemberton_uk | Updated a dated claim and added the date explicitly, per the maintenance convention. |
| 2025-01-19 | NLoughran | Plain-language pass on the opening section after feedback from a newcomer. |
| 2024-12-24 | titration_diary | Initial promotion from the source topic. Structure taken from the marked solution. |
Every edit to a maintained document records its author and a note explaining the change. An edit without a note may be reverted by any wiki editor under R9, and the revert is logged. Disagreements about content belong on the source topic rather than in the revision history (R10).
Related documents
- STEP 1 — trial digestSTEP 1 (N Engl J Med 2021): Does semaglutide 2.4 mg weekly reduce body weight in adults with obesity and no diabetes?
- STEP 2 — trial digestSTEP 2 (Lancet 2021): What weight reduction does semaglutide 2.4 mg achieve in people who also have type 2 diabetes?
- STEP 3 — trial digestSTEP 3 (JAMA 2021): What does semaglutide add on top of intensive behavioural therapy?
- STEP 4 — trial digestSTEP 4 (JAMA 2021): What happens if you stop after reaching the maintenance dose?
- STEP 8 — trial digestSTEP 8 (JAMA 2022): How does weekly semaglutide compare directly with daily liraglutide?